• In late May and early June 2026, Integrated DNA Technologies announced a collaboration with Illumina to link IDT’s xGen FFPE and cfDNA library prep to Illumina’s DRAGEN analysis, alongside Illumina’s launch of new oncology-focused automation, MRD research solutions, and expanded oncoReveal panels.
• Together, these moves deepen Illumina’s role in end-to-end clinical oncology sequencing workflows, tying its hardware, software, and assay partners more tightly into cancer research and testing.
• We’ll now examine how Illumina’s deeper integration of DRAGEN into high-volume oncology workflows could influence the company’s investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Illumina Investment Narrative Recap

To own Illumina, you have to believe that next generation sequencing will keep moving into routine clinical care, particularly oncology, and that Illumina’s installed base and software ecosystem will keep that spending tied to its platforms. The new oncology collaborations and MRD workflow build out that story, but they do not change the key near term swing factors: execution on NovaSeq X utilization and clinical uptake, versus the risk of weaker research budgets and intensifying competition.

Among the recent announcements, Illumina’s whole genome MRD research kit is the most relevant alongside the IDT deal. Both center on embedding DRAGEN and Illumina’s analysis stack into high volume oncology workflows, from fingerprinting tumors on NovaSeq systems to tracking residual disease in blood. For investors focused on clinical growth as a catalyst, this MRD offering sits at the heart of whether Illumina can deepen recurring consumables and software usage in cancer testing.

Yet even as Illumina tightens its grip on oncology workflows, investors should also weigh the risk that intensifying competition and regulatory pressures could...

Illumina's narrative projects $5.0 billion revenue and $1.0 billion earnings by 2029. This requires 5.1% yearly revenue growth and a $150.0 million earnings increase from $850.0 million today.

Uncover how Illumina's forecasts yield a $136.11 fair value, a 20% downside to its current price.

Exploring Other Perspectives

Some of the most pessimistic analysts saw Illumina reaching about US$5.0 billion of revenue and roughly US$982 million of earnings by 2029, and they worry that rising regulatory and data privacy scrutiny could slow adoption even as oncology integrations like IDT and MRD expand, so it is worth comparing their cautious view with more optimistic takes before you decide where you stand.

Explore 4 other fair value estimates on Illumina - why the stock might be worth 20% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Illumina research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Illumina research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Illumina's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 32 best rare earth metal stocks of the very few that mine this essential strategic resource.
• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.